Dr. Gerald Bernard Appel, MD

Dr. Appel practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Appel's NPI, 1306918651, was assigned on November 14, 2006. Dr. Appel graduated from Albert Einstein College of Medicine in 1972. Dr. Appel holds New York license 117207.

Dr. Appel's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Appel's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Appel is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Appel to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Appel practices. Vendor and product names are available with a free account.

Nephrology is Dr. Appel's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Appel is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Appel's licenses on file in 4 states: New York, Florida, New Jersey and Connecticut.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia and kidney disease among the conditions Dr. Appel treats.

CMS data shows 251 Medicare services from Dr. Appel across 2 procedure codes in 2024, all of them office visits, for 131 Medicare patients. Medicare paid $39,777 for them. Every service was in an office.

CMS counts 131 Medicare patients who saw Dr. Appel in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Appel's median patient age at 55, with 52% women.

In 2024, Dr. Appel wrote 90 Medicare Part D claims for 26 patients. 97% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $51 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Appel for performance year 2024, reported through an alternative payment model (APM). Dr. Appel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Appel as offering telehealth.

Dmand AI links 126 papers to Dr. Appel, published from 2005 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Immunosuppressive Agents, Glomerulonephritis, Membranous and Glomerulosclerosis, Focal Segmental. Dr. Appel has published most often in Clin J Am Soc Nephrol. Dr. Appel's most frequent co-authors are Andrew S. Bomback, MD, Jai Radhakrishnan, MD and Pietro Alessandro Ambrogio Canetta, MD.

Dmand AI links Dr. Appel to 3 clinical trials, 2 of them phase 4 studies. Conditions studied include Glomerulonephritis, IGA, Glomerulonephritis, Membranoproliferative and Nephrosis, Lipoid. Columbia University sponsors the most, 2.

CMS Open Payments shows 993 general payments to Dr. Appel from 19 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Calliditas Therapeutics US Inc. paid the most, $366,977. It also lists 2 research payments totaling $1,437 in 2024.

Dmand AI lists 6 awards for Dr. Appel, most recently America's Top Doctors in 2014.

Dr. Appel graduated from Albert Einstein College of Medicine in 1972. Dr. Appel is a member of ASN.

Dr. Appel is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.